On January 9, 2025, the results of the 2024 VENTURE50 awards, initiated by Zero2IPO Group (1945.HK) and Investment界, were finally announced!As a global leader in "AI + drug delivery," METiS TechBio has been selected for the "2024 VENTURE50 List" and the 2024 Investment Circle.「Medical Health VENTURE50"Double Rankings"。
VENTURE50: Nineteen Years of Guiding the WayVENTURE50 Investment Value Enterprise (Abbreviated as V50), founded by Zero2IPO Group (1945.HK) in 2006, has undergone nineteen years of development and refinement to become a benchmark for investment in high-growth enterprises in China.The 2024 VENTURE50, based on enterprises' different development stages and industry distributions, establishes the Prestige List, New Bud List, and Industry List. It gathers thousands of technology innovation enterprises and invites hundreds of top-tier investment institutions for evaluation. Through multiple rounds of "online selection + offline engagement," it creates an efficient interactive platform for technology enterprises and investment institutions, actively promoting the integration of industry and capital. It also supports enterprise implementation, accelerates the construction of a modern industrial system, and fully backs the high-quality development of technological innovation.METiS TechBio: AI-Driven Pioneer in Drug Delivery and DiscoveryMETiS TechBio, founded in 2020, is an innovative biotechnology company driven by artificial intelligence (AI) for drug delivery and drug discovery.By deeply integrating advanced technologies such as AI, machine learning, and quantitative simulation with drug development, METiS TechBio has achieved breakthrough progress in fields like innovative delivery material design, candidate drug selection, and formulation design. The company focuses on the development and delivery design of "programmable nucleic acid drugs," striving to meet unmet clinical needs of patients worldwide.In terms of technology development, METiS TechBio has independently developed three core technology platforms:AI-Driven Nucleic Acid Delivery System Design Platform (AiLNP): The world's first high-throughput automated LNP design platform.AI-Driven mRNA Sequence Design Platform (AiRNA): An efficient tool for empowering mRNA drug development.AI-Driven Small Molecule Formulation Design Platform (AiTEM): Achieving precise formulation design for small-molecule drugs.
Combining large models and generative AI technology, METiS TechBio has pioneeredMETiS LipidLM Lipid Language ModelAndPhatGPT Lipid Generation Model, building a million-level lipid database and achieving significant success in breaking through international patent barriers. Moreover, through innovative molecular simulation technology, the company has been able to comprehensively simulate the microscopic processes of LNPs in vivo and in vitro. Combined with a world-class experimental validation platform, this has successfully led to the development of multi-organ targeted nanomaterials, promoting the application of AI technology in the field of nanomaterials.
Driven by Innovation, Opening a New Chapter of Global CollaborationMETiS TechBio not only continuously achieves technological breakthroughs but also actively promotes a dual-driven model of "independent research and development + co-development," establishing collaborations with several internationally renowned pharmaceutical companies. Currently, the company has built multiple drug research and development pipelines, among which...The first new drug product has completed Phase III clinical trials, multiple projects have advanced to the clinical stage, and the first mRNA pipeline has entered human trials. In addition，The company has cumulatively completed financing of 300 million US dollars, andAwarded the title of "Little Giant" by the Ministry of Industry and Information Technology for its specialization, refinement, uniqueness, and innovation.Fully demonstrates the industry and capital market's high recognition of its innovation capabilities and future development.METiS TechBio's Recognition in the 2024 Investment界 "Healthcare VENTURE50" is not only an affirmation of its technical capabilities but also a significant acknowledgment of its role in driving the transformation of the global drug delivery and development landscape. Moving forward, METiS TechBio will continue to be driven by technological innovation, collaborating with global partners to bring revolutionary therapies to patients and make greater contributions to global health.
METiS TechBio Dr. Lai Caida Year-End Speech Video ?
